Norges Bank Next Cure, Inc. Transaction History

Norges Bank

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.29 - $1.84 $66,951 - $95,496	-51,900 Closed	0 $0
Q2 2023 Aug 14, 2023	SELL	$1.47 - $1.86 $76,293 - $96,534	-51,900 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$1.46 - $1.83 $75,774 - $94,977	51,900 New	51,900 $76,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $3.07 $62,280 - $159,333	51,900 New	51,900 $73,000
Q3 2022 Nov 13, 2023	BUY	$2.72 - $5.19 $141,168 - $269,361	51,900 New	51,900 $154,000
Q2 2022 Aug 14, 2023	BUY	$3.38 - $5.27 $175,422 - $273,513	51,900 New	51,900 $243,000
Q1 2022 May 09, 2022	SELL	$4.76 - $6.24 $247,044 - $323,856	-51,900 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$5.7 - $9.1 $295,830 - $472,290	51,900 New	51,900 $311,000
Q3 2021 Nov 14, 2022	BUY	$6.74 - $8.02 $349,806 - $416,238	51,900 New	51,900 $350,000
Q3 2021 Nov 05, 2021	SELL	$6.74 - $8.02 $355,872 - $423,456	-52,800 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$7.6 - $10.28 $401,280 - $542,784	52,800 New	52,800 $424,000
Q2 2021 Aug 10, 2021	SELL	$7.6 - $10.28 $1.67 Million - $2.25 Million	-219,254 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$9.81 - $13.88 $2.15 Million - $3.04 Million	219,254 New	219,254 $2.2 Million

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $26.9M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.